Mobigel Spray 4% W/W Cutaneous Spray Solution
SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE MEDICINAL PRODUCT
Mobigel Spray 4% cutaneous spray, solution
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Each 1g of solution contains 40 mg of diclofenac sodium.
Excipients with known effects: 100 mg Soybean lecithin / gram solution, 150 mg propylene glycol (E1520)/ gram solution
For a full list of excipients, see section 6.1.
3 PHARMACEUTICAL FORM
Cutaneous spray, solution.
A golden-yellow, transparent solution, which turns to a gel-like consistency after administration.
4 CLINICAL PARTICULARS
4.1 Therapeutic indications
For the local symptomatic relief of mild to moderate pain and inflammation following acute blunt trauma of small and medium-sized joints and periarticular structures.
4.2 Posology and method of administration
Posology
Adults
Sufficient solution should be sprayed onto the skin to ensure a generous covering of Mobigel® Spray 4% cutaneous spray, solution over the affected site. Normally, 4-5 pump strokes (0.8-1.0 g of spray containing 32-40 mg of diclofenac sodium) would be required. The treatment should be repeated 3 times a day at regular intervals. The maximum daily dose is 15 pump strokes (3.0 g of spray containing 120 mg of diclofenac sodium).
Mobigel® Spray 4% cutaneous spray, solution should be massaged gently into the skin. After this the hands should be washed unless they are the site to be treated. After application some minutes for drying should be allowed before dressing or binding the treated area.
The treatment may be discontinued when the symptoms (pain and swelling) have subsided. Treatment should not be continued beyond 7-8 days without review. The patient is requested to consult the doctor if no improvement is seen after 3 days.
Older people
The posology is the same as for adults.
Paediatric population
There are insufficient data on efficacy and safety available for the children and adolescents below 14 years of age (see also contraindications section 4.3).
In children aged 14 years and over, if this product is required for more than 7 days for pain relief or if the symptoms worsen the patient/parents of the adolescent is/are advised to consult a doctor.
Patients with hepatic or renal impairment
For the use of Mobigel® Spray 4% cutaneous spray, solution in patients with hepatic or renal insufficiency see section 4.4.
Method of administration
For cutaneous use only.
4.3 Contraindications
Hypersensitivity to diclofenac, acetylsalicylic acid or other non-steroidal antiinflammatory drugs (NSAIDs), peanut, soya or to any of the excipients listed in section 6.1.
Patients with or without asthma in whom attacks of asthma, urticaria or acute rhinitis are precipitated by aspirin or other non-steroidal anti-inflammatory agents (NSAIDs).
During the third trimester of pregnancy.
Paediatric population: the use in children and adolescents aged less than 14 years is not recommended.
4.4 Special warnings and precautions for use
The possibility of systemic adverse events from application of Mobigel Spray 4% cutaneous spray, solution cannot be excluded if the preparation is used on large areas of skin and over a prolonged period (see the product information on systemic forms of diclofenac).
Mobigel Spray 4% cutaneous spray, solution should be applied only to intact nondiseased skin, and not to skin wounds or open injuries. It should not be allowed to come into contact with the eyes or mucous membranes and should not be ingested.
Mobigel Spray 4% cutaneous spray, solution can be used with non-occlusive bandages but should not be used with an airtight occlusive dressing.
Patients should be warned against excessive exposure to sunlight in order to reduce the incidence of photosensitivity.
Discontinue the treatment if a skin rash develops after applying the product.
The concomitant use of Mobigel Spray 4% cutaneous spray, solution with oral NSAIDs should be cautioned as the incidence of systemic side effects may increase (see section 4.5).
Where Mobigel Spray 4% cutaneous spray, solution is applied to a relatively large area of skin (i.e. more than 600 square centimetres of the body surface) and over a prolonged period (i.e. more than 4 weeks), the possibility of systemic side-effects cannot be completely excluded. If such usage is envisaged, the data sheet on diclofenac oral dosage forms should be consulted (for example, there is the potential for hypersensitivity, asthmatic and renal adverse reactions).
Bronchospasm may be precipitated in patients suffering from or with previous history of bronchial asthma or allergenic disease.
Mobigel Spray 4% cutaneous spray, solution should only be used with caution in patients with a history of peptic ulcer, hepatic or renal insufficiency, or bleeding diathesis, or inflammatory bowel disease, as isolated cases with topical diclofenac have been reported.
Mobigel Spray 4% cutaneous spray, solution contains propylene glycol which may cause skin irritation in some people.
Mobigel Spray 4% cutaneous spray, solution contains peppermint oil which may cause allergic reactions.
4.5 Interaction with other medicinal products and other forms of interaction
Since systemic absorption of diclofenac from a topical application of Mobigel Spray 4% cutaneous spray, solution is very low such interactions are very unlikely.
Concurrent acetylsalicylic acid or other NSAIDs may result in an increased incidence of adverse reactions (see section 4.4).
4.6 Fertility, pregnancy and lactation Pregnancy
The systemic concentration of Mobigel Spray 4% cutaneous spray, solution is lower after topical administration, compared to oral formulations. With reference to experience from treatment with NSAIDs with systemic uptake, the following is recommended:
Inhibition of prostaglandin synthesis may adversely affect the pregnancy and/or the embryo/foetal development. Data from epidemiological studies suggest an increased risk of miscarriage and of cardiac malformation and gastroschisis after use of a prostaglandin synthesis inhibitor in early pregnancy. The absolute risk for cardiovascular malformation was increased from less than 1%, up to approximately 1.5%. The risk is believed to increase with dose and duration of therapy. In animals, administration of a prostaglandin synthesis inhibitor has been shown to result in increased pre-and post-implantation loss and embryo-foetal lethality. In addition, increased incidences of various malformations, including cardiovascular, have been reported in animals given a prostaglandin synthesis inhibitor during the organogenetic period.
During the first and second trimester of pregnancy, Mobigel Spray 4% cutaneous spray, solution should not be given unless clearly necessary. If Mobigel Spray 4% cutaneous spray, solution is used by a woman attempting to conceive, or during the first and second trimester of pregnancy, the dose should be kept as low and duration of treatment as short as possible.
During the third trimester of pregnancy, all prostaglandin synthesis inhibitors may expose the foetus to:
• cardiopulmonary toxicity (with premature closure of the ductus arteriosus and pulmonary hypertension);
• renal dysfunction, which may progress to renal failure with oligo-hydroamniosis;
The mother and the neonate, at the end of pregnancy, to:
• possible prolongation of bleeding time, an anti-aggregating effect which may occur even at very low doses.
• inhibition of uterine contractions resulting in delayed or prolonged labour.
Consequently, diclofenac is contraindicated during the third trimester of pregnancy.
Breast-feeding
Like other NSAIDs, diclofenac passes into breast milk in small amounts. However, at therapeutic doses of Mobigel Spray 4% cutaneous spray, solution no effects on the suckling child are anticipated. Because of a lack of controlled studies in lactating women, the product should only be used during lactation under advice from a healthcare professional. Under this circumstance, Mobigel Spray 4% cutaneous spray, solution should not be applied on the breasts of nursing mothers, nor elsewhere on large areas of skin or for a prolonged period of time (see section 4.4).
4.7 Effects on ability to drive and use machines
Cutaneous application of Mobigel Spray 4% cutaneous spray, solution has no influence on the ability to drive and use machines.
4.8 Undesirable effects
Skin disorders are commonly reported.
Adverse reactions (Table 1) are ranked under heading of frequency, the most frequent first, using the following convention: very common (> 1/10); common (> 1/100 to < 1/10); uncommon (> 1/1,000 to < 1/100); rare (> 1/10,000 to < 1/1,000); very rare (< 1/10,000), or not known (can not to be estimated from available data). Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness.
Table 1
|
Immune system disorder | |
|
Very rare |
Hypersensitivity (including urticaria), angioneurotic oedema |
|
Infections and infestations | |
|
Very rare |
Rash pustular |
|
Respiratory, thoracic and mediastinal disorders | |
|
Very rare |
Asthma |
|
Skin and subcutaneous tissue disorders | |
|
Common |
Rash, eczema, erythema, dermatitis (including dermatitis contact), pruritus* |
|
Rare |
Dermatitis bullous |
|
Very rare |
Photosensitivity reaction |
|
Not known |
Application site reaction, dry skin, burning sensation |
* Pruritus has been reported at a frequency of 0.9% in a clinical trial, 236 patients with ankle distortions were treated with 4-5 pump strokes of Mobigel Spray 4% cutaneous spray, solution t.i.d. (120 patients) or placebo (116 patients) for 14 days.
Undesirable effects may be reduced by using the minimum effective dose for the shortest possible duration. The total single dose of product should not exceed 1.0 g of spray.
Nevertheless during long term treatment (> three weeks) and/or when treating large areas (i.e. more than 600 square centimetres of the body surface) there is a possibility of systemic adverse reactions. Reactions like abdominal pain, dyspepsia, gastric and renal disorders may occur.
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via Yellow Card Scheme Website: www.mhra.gov.uk/yellowcard
4.9 Overdose
The low systemic absorption of topical diclofenac renders overdose very unlikely.
However undesirable effects similar to those observed following an overdose of diclofenac tablets can be expected if Mobigel Spray 4% cutaneous spray, solution is inadvertently ingested (i.e. a 15 ml spray bottle containing 500 mg of diclofenac sodium).
In the event of accidental ingestion resulting in significant systemic adverse effects, general therapeutic measures normally adopted to treat poisoning with non-steroidal anti-inflammatory medicines should be used. Gastric decontamination and the use of activated charcoal should be considered, especially within a short time of ingestion.
5 PHARMACOLOGICAL PROPERTIES
5.1 Pharmacodynamic properties
Pharmacotherapeutic group: Antiinflammatory preparations, non-steroids for topical use.
ATC code: M02AA 15
Sodium diclofenac is a non-steroidal anti-inflammatory drug (NSAID) which has also analgesic properties. The inhibition of prostaglandin synthesis is considered to be an essential part of its mode of action.
5.2 Pharmacokinetic properties
After cutaneous application of 1.5 g Mobigel Spray 4% cutaneous spray, solution a rapid onset of diclofenac absorption can be observed leading to measurable plasma levels of about 1 ng/ml as early as 30 minutes and to maximum levels of about 3 ng/ml at about 24 hours after application.
The achieved systemic concentrations of diclofenac are about 50 times lower than those achieved following oral administration of equivalent amounts of diclofenac. Systemic plasma levels are not supposed to contribute to the efficacy of Mobigel Spray 4% cutaneous spray, solution.
Diclofenac is extensively bound to plasma proteins (about 99 %).
5.3 Preclinical safety data
In rabbit skin, Mobigel Spray 4% cutaneous spray, solution is classified as non-irritant.
Preclinical data based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity and carcinogenic potential of diclofenac reveal no special hazard for humans other than already mentioned in earlier sections of this SPC.
In rats and rabbits oral doses of diclofenac were not teratogenic but caused embryotoxicity at maternally toxic doses.
Diclofenac did not affect fertility in rats but inhibited ovulation in rabbits and reduced implantation in rats.
In rats, diclofenac resulted in dose-dependent constriction of the fetal ductus arteriosus, dystocia and delayed parturition.
6 PHARMACEUTICAL PARTICULARS
6.1 List of excipients
Isopropyl alcohol
Soy bean lecithin Ethanol
Disodium phosphate dodecahydrate Sodium dihydrogen phosphate dihydrate Disodium edetate Propylene glycol (E1520)
Peppermint oil Ascorbyl palmitate Hydrochloric acid 10% (w/w)
Sodium hydroxide 10% (w/w)
Purified water.
6.2 Incompatibilities
Not applicable.
6.3 Shelf life
Unopened bottle (30 ml and 15 ml): 3 years Unopened bottles (10 ml): 2 years
In-use: 6 months
6.4 Special precautions for storage
Store in the original package.
6.5 Nature and contents of container
Glass bottle with metering pump/nozzle/spray valve and cap, 7.5 g, 12.5 g and 25 g solution.
Not all pack sizes may be marketed.
6.6
Special precautions for disposal
No special requirements.
7 MARKETING AUTHORISATION HOLDER
MIKA PHARMA GMBH
AN DER RHEINS CHANZE 1 67059 LUDWIGSHAFEN GERMANY
8 MARKETING AUTHORISATION NUMBER(S)
PL 18017/0005
9 DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION
Date of first authorisation: 13/05/2002 Date of latest renewal: 13/05/2007
10 DATE OF REVISION OF THE TEXT
02/10/2015
11 DOSIMETRY (IF APPLICABLE)
INSTRUCTIONS FOR PREPARATION OF RADIOPHARMACEUTICALS (IF APPLICABLE)